GLP-1 Market
LLY $1166.51 ▼ -1.4% NVO $38.06 ▼ -1.3% PFE $28.37 ▼ -0.1% VKTX $26.65 ▼ -6.0% KLRA $10.77 ▼ -4.9% GPCR $22.31 ▼ -6.7% RHHBY $53.77 ▼ -0.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Bexagliflozin

Company
Baylor Research Institute
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026

Find a Clinical Trial Near Me

See recruiting studies for Bexagliflozin and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05612594

    Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

    Not yet reported Yale University 164 participants Est. completion 2027-09 2 sites Stand-alone
    Other conditions: Sleep Apnea
    View official trial listing →
  • Recruiting NCT NCT06600178

    Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

    Not yet reported University of Virginia 150 participants Est. completion 2029-06-29 1 site Stand-alone
    Cardiovascular disease Other conditions: Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
    View official trial listing →
  • Completed NCT NCT01377844

    Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

    Not yet reported Theracos 288 participants Est. completion 2013-12 11 sites
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02390050

    A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Theracos 292 participants Est. completion 2016-06-03 50 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02558296

    Bexagliflozin Efficacy and Safety Trial

    Not yet reported Theracos 1700 participants Est. completion 2019-10-23 157 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02715258

    Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

    Not yet reported Theracos 210 participants Est. completion 2017-04 23 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02769481

    Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

    Not yet reported Theracos 426 participants Est. completion 2019-06-14 45 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02820298

    Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

    Not yet reported Theracos 25 participants Est. completion 2016-08-29 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02836873

    Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

    Not yet reported Theracos 312 participants Est. completion 2018-01-11 56 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02956044

    Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

    Not yet reported Theracos 54 participants Est. completion 2017-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03115112

    Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

    Not yet reported Theracos 386 participants Est. completion 2018-10-31 56 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03167411

    Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

    Not yet reported Theracos 20 participants Est. completion 2017-06-29 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03197324

    Bexagliflozin Drug/Drug Interaction Study With Digoxin

    Not yet reported Theracos 20 participants Est. completion 2017-09-17 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03259789

    Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

    Not yet reported Theracos 351 participants Est. completion 2019-01-23 43 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03296800

    Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

    Not yet reported Theracos 48 participants Est. completion 2017-12-06 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT03417076

    Absolute Bioavailability Study With Bexagliflozin

    Not yet reported Theracos Est. completion 2018-09-16 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03514641

    An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

    Not yet reported, Not yet reported Theracos 673 participants Est. completion 2018-11-30 87 sites
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT03557658

    Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

    Not yet reported Theracos 16 participants Est. completion 2018-12-26 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07188545

    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
    Metabolic syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT07325435

    Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

    Not yet reported MaryAnn Banerji 60 participants Est. completion 2028-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Enrolling by invitation NCT NCT07547878

    Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

    Not yet reported Baylor Research Institute 64 participants Est. completion 2029-03-31 1 site
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Bexagliflozin, BRENZAVVY

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.